FDA Brief

Warning letters Drugs

FDA warning letter to

Outin Futures Corp.

High riskIssued Sep 25, 2024Posted Oct 15, 2024Center for Drug Evaluation and Research (CDER)

FDA warned Outin Futures, a Korean drug manufacturer, of CGMP violations and sunscreen misbranding after a March 2024 inspection.

What happened

FDA inspected Outin Futures' drug manufacturing facility in Chungju, Korea, from March 25 to 29, 2024. Investigators found laboratory records missing failed test results, deleted electronic raw data and disabled audit trails, a quality control unit that released a batch on retest without investigation, and inadequate process and cleaning validation. FDA also reviewed the label of the company's NEOGEN DERMALOGY AIRY SUNSCREEN SPF 50 and found required information and warnings missing.

What FDA found

  1. Lab records did not include all test data: a sunscreen batch failed its strength test several times between September 2022 and March 2023, and those failing results were not recorded or investigated.

    21 CFR 211.194(a)
  2. Laboratory computer systems had no restricted access or adequate controls, so raw data for batches on the U.S. market was deleted and could not be recovered, and audit trails on some systems were turned off.

    21 CFR 211.68(b)
  3. The quality control unit did not have or use the authority and procedures to approve or reject products; it released a batch on a retest without investigation and did not qualify the active ingredient supplier or contract testing lab, use change control, or do annual product reviews.

    21 CFR 211.22(a) and (d)
  4. Manufacturing process validation did not check whether the active ingredient was evenly mixed in the bulk product, and equipment cleaning validation was inadequate.

    21 CFR 211.100(a)
  5. The sunscreen label is missing the required statement telling users to protect the product from excessive heat and direct sun.

    FD&C Act section 502(c), 21 U.S.C. 352(c)
  6. The sunscreen label is missing the required warning not to use the product on damaged or broken skin, and lacks a U.S. address or phone number for reporting serious adverse events.

    FD&C Act sections 502(f)(2) and 502(x), 21 U.S.C. 352(f)(2) and 352(x)

What FDA wants

FDA tells the company to reply in writing within 15 working days describing what it has done to fix the violations and prevent recurrence, or to explain any delay and give a completion schedule. FDA also strongly recommends hiring a qualified consultant to audit the operation and check the corrective actions, and notes the firm was placed on Import Alert 66-40 on August 29, 2024.

Who should pay attention

  • U.S. distributors and retailers selling Korean-made sunscreens and OTC drugs
  • Brands that use this company as a contract manufacturer
  • Companies buying sunscreen active ingredients or finished OTC drug product from Korean suppliers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  3. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  4. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk